retatrutide dosing phase 2 trial isn't a GLP-1. It's not a dual agonist. It's a triple hormone receptor agonist — activating GIP, GLP-1, and glucagon simultaneously. Three receptors. Three mechanisms. One protocol. Swipe to see what Retatrutide vs Semaglutide: Triple vs

Resnick O, Bril F, Beauchamp G

The L-Cell Function L-cells perform several critical metabolic functions: GLP-1 Production: Convert proglucagon (precursor protein) into active GLP-1 hormone Nutrient Sensing: Detect proteins, fats, and carbohydrates passing through the intestine Gut-Brain Communication: Release peptide YY (PYY) that signals satiety to the brain Metabolic Regulation: Respond to short-chain fatty acids produced by gut bacteria Research demonstrates that L-cell density and function can be influenced by dietary patterns, gut microbiome composition, and specific nutrients

It sits within the regulatory layer covering laboratory reagents and research chemicals, not the layer governing human therapeutics

That call belongs entirely to the reviewing clinician

Data on weight loss, comorbidities, and adverse events were collected over a median follow-up of 1 year

While the clinical evaluation of GLP-1MK-801 for weight loss awaits, efforts to broaden the scope of developing peptide-mediated targeting of ion channels are encouraged and should not be restricted to metabolic diseases